Literature DB >> 27336213

Role of ethnicity in treating uterine fibroids with ulipristal acetate.

Ally Murji1, Rebecca Crosier2, Tiffany Chow2, Xiang Y Ye3, Lindsay Shirreff4.   

Abstract

OBJECTIVE: To study differences in treatment effect between black and white premenopausal women prescribed ulipristal acetate (UPA) for symptomatic uterine fibroids.
DESIGN: Prospective observational cohort study.
SETTING: Gynecology clinics. PATIENT(S): Premenopausal women aged 18-55 years, at least one symptomatic uterine fibroid, UPA-naïve, and no contraindications for UPA treatment. INTERVENTION(S): One 3-month course of UPA at 5 mg daily. MAIN OUTCOME MEASURE(S): Patients' ethnicity self-identification adapted from Statistics Canada National Household Survey. Change in fibroid symptoms according to Uterine Fibroid Symptoms Quality of Life Questionnaire symptom severity and health-related quality of life score. Bleeding symptoms and amenorrhea rates according to Aberdeen Bleeding Score. RESULT(S): A total of 148 patients enrolled (45 black, 59 white, 44 other ethnicity). Black patients were younger (40.3 y vs. 44.5 y) with larger uteri (523 mL vs. 351 mL) than white counterparts. Baseline symptom severity was similar between groups. After 3 months of UPA treatment, both groups experienced similar improvements in symptom severity. White women had 52% greater improvement in bleeding score (-40.3 vs. -26.5) and were more likely to be amenorrheic at the end of treatment (66% vs. 41%). Both groups experienced adverse events at similar frequencies. Black women were more dissatisfied with UPA compared with white women (27.3% vs. 8%). CONCLUSION(S): Black women had greater fibroid burden at baseline. Both ethnicities had similar improvement in fibroid symptomatology following UPA treatment, but white women experienced higher amenorrhea rates. Black women were more dissatisfied with UPA treatment, which may be related to the lower amenorrhea rates.
Copyright © 2016 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Uterine leiomyoma; ethnicity; medical therapy; ulipristal acetate

Mesh:

Substances:

Year:  2016        PMID: 27336213     DOI: 10.1016/j.fertnstert.2016.06.012

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

Review 1.  Selective progesterone receptor modulators (SPRMs) for uterine fibroids.

Authors:  Ally Murji; Lucy Whitaker; Tiffany L Chow; Mara L Sobel
Journal:  Cochrane Database Syst Rev       Date:  2017-04-26

Review 2.  Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.

Authors:  Karly P Garnock-Jones; Sean T Duggan
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

3.  Disparities in Treatment Decisions for Abnormal Uterine Bleeding.

Authors:  Lulu Yu; Bhavana Janga; Rebecca McAlister; Donna B Jeffe; Tammy Sonn
Journal:  J Womens Health (Larchmt)       Date:  2021-02-12       Impact factor: 3.017

4.  Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation.

Authors:  Gabriele Sutter; Matthias Frei; Marcus-Hillert Schultze-Mosgau; Kathrin Petersdorf; Christian Seitz; Bart A Ploeger
Journal:  Br J Clin Pharmacol       Date:  2021-08-25       Impact factor: 3.716

Review 5.  Uterine Fibroids: Burden and Unmet Medical Need.

Authors:  Ayman Al-Hendy; Evan Robert Myers; Elizabeth Stewart
Journal:  Semin Reprod Med       Date:  2017-11-03       Impact factor: 1.303

Review 6.  Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur?

Authors:  Funlayo Odejinmi; Reeba Oliver; Rebecca Mallick
Journal:  Womens Health (Lond)       Date:  2017-11-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.